Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 24, 2024, titled "Zydus Lifesciences announces completion of Enrolment for Phase II clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)."
Press Release May 24 2024
Filed with NSE · · 3 pages · English
Summary by 6ix AI
The trial will evaluate the safety and efficacy of Usnoflast in ALS patients, with primary and secondary endpoints focused on functional and biological measures. This press release aims to inform investors and the exchange about the progress of Zydus Lifesciences' clinical research efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release May 22 2024
- Press Release May 17 2024
- Press Release May 11 2024
- Press Release May 09 2024
- Press Release May 04 2024
Later from Zydus Lifesciences
- Press Release Jun 14 2024
- Press Release Jun 28 2024
- Press Release Jul 04 2024
- Press Release Jul 10 2024
- Press Release (Revised) Jul 10 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences